Eli Lilly has achieved explosive revenue growth fueled by its expanding portfolio of next-generation metabolic and weight-loss drugs.
Novo Nordisk maintains a deep global reach with established diabetes and obesity treatments currently available in more than 50 countries.
Which of these pharmaceutical giants offers a more compelling risk-to-reward profile for investors looking toward 2027?
The global demand for next-generation metabolic treatments has sparked a fierce competition, forcing retail investors to decide between Eli Lilly & Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) for their long-term portfolios.
Eli Lilly focuses on drug discovery and marketing across 90 countries, while Novo Nordisk leverages its Danish roots to lead in diabetes and rare disease therapies. Both companies are currently scaling their manufacturing capacity to meet soaring patient needs. This comparison clarifies which business model and valuation currently offer the more compelling opportunity through 2027.
Eli Lilly develops and markets human pharmaceutical products in approximately 90 countries. In the U.S., the company relies on wholesale distributors like McKesson Corp. (NYSE:MCK), Cencora Corp. (NYSE:COR), and Cardinal Health (NYSE:CAH), which each account for significant revenue. To expand access, it uses the LillyDirect platform and manages collaborations with partners like Innovent Biologics (OTC:IVBXF).
Financial performance has been robust for this titan among pharmaceutical stocks. In the 12 months ended Sept. 30, 2026, revenue reached about $86.5 billion, representing revenue growth of approximately 45.5%. Net income for the same period was around $27.6 billion, highlighting significant bottom-line expansion.
As of its December 2025 balance sheet, the current ratio is nearly 1.6x, meaning current assets cover current liabilities 1.6 times over. The debt-to-equity ratio is roughly 1.6x, indicating that total debt is 1.6 times the amount of shareholder equity. In the fiscal year ended Dec. 31, 2025, free cash flow was approximately $9.0 billion.
Novo Nordisk A/S focuses on diabetes and obesity treatments, with its Wegovy medication now available in 52 countries. The company also operates in the rare disease and cardiovascular therapy segments across major global regions. It manages a complex distribution network to reach patients in the U.S., Europe, emerging markets, and China.
Recent financial results show steady progress for the Denmark-based manufacturer. In the 12 months ended Sept. 30, 2026, revenue reached about $49.0 billion, reflecting revenue growth of approximately 5.7%. Net income for these twelve months reached roughly $16.6 billion, showing the company's ability to maintain a strong net margin.
The company carries a strong financial position relative to its liabilities. As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 0.7x, meaning total debt is 0.7 times shareholder equity. The current ratio of approximately 0.8x indicates current assets cover 80% of current liabilities, while free cash flow reached around $4.3 billion in the fiscal year ended Dec. 31, 2025.
Eli Lilly faces significant research and development risk because pharmaceutical innovation is both expensive and uncertain. The company also deals with legal challenges regarding drug pricing and the potential off-label marketing of products like Mounjaro. Revenue concentration remains a concern, as a limited number of products drive a large portion of consolidated results.
Novo Nordisk A/S must navigate intense competition and strict regulatory oversight in multiple international jurisdictions. The company is subject to pricing pressure from government healthcare systems and private insurers. Additionally, maintaining a global supply chain for biologic drugs poses ongoing operational risks that could impact future results.
Novo Nordisk appears much more affordable on a relative basis, as its valuation multiples sit well below the high levels currently assigned to Eli Lilly.
| Metric | Eli Lilly | Novo Nordisk A/S |
|---|---|---|
| Forward P/E | 40.5x | 12.3x |
| P/S ratio | 15.6x | 3.7x |
Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.
The Forward P/E compares the stock price to future earnings estimates. Meanwhile, the P/S ratio measures the market cap against sales over the past twelve months.
These are two GLP-1 giants, but they are trending in different directions.
Novo Nordisk has the blockbuster drugs Wegovy and Ozempic (the same drug marketed for different purposes), but faces investor doubts about its market position given a deal with the federal government to lower prices for the GLP-1s, the emergence of generic competitors, and the apparent advances by Eli Lilly in developing weight loss drugs expected to be superior to Novo's offerings.
Still, the introduction of the once-a-day Wegovy pill in the U.S. has been a resounding success, and the business has a patent on injectable Ozempic/Wegovy till 2032, providing it some competitive moat. Still, Wall Street sees sales around the same level as last year in fiscal 2026, with net income contracting a touch in Novo's reporting currency, as pricing pressures erode margins slightly. Long-term, analysts expect the company to reverse the 2026 decline and start growing modestly again as new products come online.
Eli Lilly & Co., meanwhile, is perhaps the fastest-growing pharmaceutical stock around, with a massive sales jump last year. Lilly is riding a wave of success with its GLP-1 drugs Zepbound for weight loss and Mounjaro for diabetes control. There is still plenty of growth left in the treatment, and that is expected to power revenue up more than a third in 2026, to $91.7 billion, with close to $31 billion in net income.
Its next weight-loss drug, Retatrutide, is hotly anticipated for its triple-agonist approach, which is expected to exceed the weight-loss results of Zepbound. The company is also targeting less affluent customers with a lower-cost GLP pill called Foundayo, which it sells directly to consumers.
Besides GLP-1s, Lilly is working on a small interfering RNA therapeutic targeting lipoprotein(a) for the prevention of atherosclerotic cardiovascular disease in patients with elevated lipoprotein(a) levels. Analysts believe it will be a blockbuster ($1 billion or more in lifetime revenue) if approved.
Lilly shares come at a premium, but that is buying into future growth, which appears unabated, at least for the foreseeable future. Long-term investors should be willing to pay up for Eli Lilly and enjoy the many years of growth ahead. Novo Nordisk, meanwhile, is bargain-priced, but shares aren't a bargain if management can't find a way to get real growth going again.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*
Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2026.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.